ArticleBMJ open2026

Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

Hui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.